FGFR Inhibition: Understanding and Overcoming Resistance
Related Experiment Video
Updated: Jul 17, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Abhishek Tripathi1, Daneng Li1, Sumanta K Pal1
1Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California.
Summary:
Facchinetti and colleagues provide key insights into the evolution of resistance to fibroblast growth factor receptor (FGFR) inhibitors, including the development of kinase domain mutations and activation of the PI3K-AKT signaling axis. In a separate study, Subbiah and colleagues report extensive preclinical data and initial clinical data for RLY-4008, an FGFR2-selective inhibitor that is poised to minimize toxicity and overcome resistance through greater potency and selectivity. See related article by Facchinetti et al., p. 1998 (5). See related article by Subbiah et al., p. 2012 (7).
Insights
Fibroblast growth factor receptor (FGFR) inhibitors face evolving resistance through mutations and signaling pathway activation. A new FGFR2-selective inhibitor, RLY-4008, shows promise in overcoming resistance and reducing toxicity.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Fibroblast growth factor receptor (FGFR) inhibitors are crucial in cancer therapy.
- Resistance to FGFR inhibitors develops through mechanisms like kinase domain mutations and PI3K-AKT pathway activation.
- Understanding these resistance mechanisms is vital for developing more effective treatments.
More Related Videos
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
Treatment Resistant Cancers
Mitogens and the Cell Cycle
GPCR Desensitization
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Feedback Inhibition
GPCRs Regulate Adenylyl Cylase Activity